Description

Lamistar 30 (Lamivudine/Stavudine) – Prescription Antiretroviral Medicine for HIV-1 Treatment

Lamistar 30 is a prescription antiretroviral medicine formulated with Lamivudine 150 mg and Stavudine 30 mg, two nucleoside reverse transcriptase inhibitors (NRTIs) used as part of combination antiretroviral therapy for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection in adults and eligible adolescents. These medicines work by inhibiting the HIV reverse transcriptase enzyme, reducing the virus’s ability to replicate and helping lower the viral load while supporting immune system function.

Lamistar 30 helps maintain viral suppression and reduce the risk of HIV-related complications when taken consistently as part of a complete HIV treatment regimen. It does not cure HIV infection and should always be used in combination with other prescribed antiretroviral medicines under the supervision of a qualified healthcare professional.

The medicine is prescribed only after careful medical evaluation, as the appropriate dose depends on the patient’s body weight, kidney function, previous treatment history, and overall health condition. Due to the long-term safety concerns associated with Stavudine, this combination is generally reserved for situations where alternative treatment options are not suitable.

• Key Features

1. Contains Lamivudine 150 mg and Stavudine 30 mg per tablet
2. Prescription-only antiretroviral medication
3. Fixed-dose oral tablet for convenient administration
4. Used as part of combination therapy for HIV-1 infection
5. Helps suppress HIV viral replication
6. Dose determined according to body weight and kidney function
7. Manufactured under quality pharmaceutical standards

How to Take Lamistar 30

For the best therapeutic effect, take Lamistar 30 exactly as directed by your healthcare provider. The medicine is generally taken twice daily, with or without food. Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your doctor.

Take the medicine at the same time every day and avoid missing doses. Do not discontinue treatment without medical advice, as doing so may increase the risk of viral resistance and treatment failure.

• General Dosage Reference

Medical Condition	Recommended Adult Dose
HIV-1 Infection	One tablet twice daily as part of combination therapy
Body Weight-Based Therapy	Dose may vary according to body weight
Renal Impairment	Dose adjustment may be required
Other HIV Treatment Regimens	As directed by the treating physician

The exact dosage should always be determined by your healthcare provider based on body weight, kidney function, treatment history, and current HIV treatment guidelines.

Safety Information

Before starting Lamistar 30, tell your healthcare provider if you have kidney disease, liver disease, hepatitis B infection, pancreatitis, peripheral neuropathy, diabetes, or any known allergy to Lamivudine, Stavudine, or any ingredients in the medicine.

Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using this medicine. Inform your physician about all prescription medicines, over-the-counter drugs, vitamins, and herbal supplements to reduce the risk of drug interactions.

Most people tolerate Lamistar 30 well when taken as prescribed. However, some individuals may experience mild side effects such as headache, nausea, diarrhea, abdominal discomfort, dizziness, or tiredness. Serious side effects may include lactic acidosis, pancreatitis, peripheral neuropathy, liver toxicity, and severe allergic reactions. Seek immediate medical attention if you experience severe abdominal pain, numbness or tingling in the hands or feet, yellowing of the skin or eyes, unusual muscle weakness, or difficulty breathing.

Patients with hepatitis B infection should not stop Lamivudine-containing medicines without medical supervision, as discontinuation may worsen hepatitis B.

Product Specifications

Specification	Information
Brand	Lamistar 30
Generic Name	Lamivudine / Stavudine
Active Ingredients	Lamivudine 150 mg + Stavudine 30 mg
Strength	150 mg / 30 mg
Dosage Form	Oral Tablet
Drug Class	Antiretroviral (NRTI Combination)
Route of Administration	Oral
Prescription Status	Prescription Required
Storage	Store below 25°C in a cool, dry place away from moisture and direct sunlight

Frequently Asked Questions

Can Lamistar 30 be taken with food?

Yes. Lamistar 30 may generally be taken with or without food unless your healthcare provider advises otherwise.

Is Lamistar 30 a cure for HIV?

No. Lamistar 30 does not cure HIV infection. It helps suppress HIV replication when used as part of a complete antiretroviral treatment regimen.

Can Lamistar 30 be used alone?

No. Lamistar 30 should always be used together with other prescribed antiretroviral medicines according to your healthcare provider’s recommendations.

Why is regular monitoring important while taking Lamistar 30?

Regular medical monitoring helps detect possible side effects such as peripheral neuropathy, pancreatitis, lactic acidosis, and liver problems, ensuring safe and effective treatment.

What should I do if I miss a dose?

Take the missed dose as soon as you remember if it is not close to your next scheduled dose. Do not take two doses together. Consult your healthcare provider if you are unsure.